Novo-Catalent deal to ease Wegovy supply concerns (NYSE:NVO)

0


Still life of Wegovy an injectable prescription weight loss medicine that has helped people with obesity.

UCG/Universal Images Group via Getty Images

The ongoing supply constraints for Novo Nordisk’s (NVO) hugely popular weight loss therapy, Wegovy, are expected to ease as the company’s parent, Novo Holdings, agreed to acquire the U.S. contract manufacturer Catalent (NYSE:CTLT) in a $16.5B deal on Monday.

Shortly



Source link

Leave A Reply

Your email address will not be published.